Spago Nanomedical AB (publ) (STO:SPAGO)

Sweden flag Sweden · Delayed Price · Currency is SEK
0.116
-0.011 (-8.33%)
Mar 9, 2026, 5:29 PM CET
-46.53%
Market Cap 76.41M
Revenue (ttm) 4.82M
Net Income (ttm) -26.55M
Shares Out 661.57M
EPS (ttm) -0.07
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 83,477
Average Volume 168,932
Open 0.126
Previous Close 0.126
Day's Range 0.112 - 0.126
52-Week Range 0.084 - 0.460
Beta 1.31
RSI 43.83
Earnings Date May 6, 2026

About Spago Nanomedical AB

Spago Nanomedical AB (publ), a clinical phase nanomedicine company, engages in the development of nanomedicines for cancer diagnostics and treatment primarily in Sweden. Its products include SpagoPix (SN132D), an MRI contrast agent, which is under Phase I development stage for the treatment of breast cancer, and under Phase II development stage for the treatment liver and pancreas cancer, as well as offers Tumorad (SN201), a radionuclide therapy for treatment of advanced and metastatic cancer, under preclinical development stage. The company wa... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 1999
Employees 7
Stock Exchange Nasdaq Stockholm
Ticker Symbol SPAGO
Full Company Profile

Financial Performance

In 2025, Spago Nanomedical AB's revenue was 4.82 million, a decrease of -27.53% compared to the previous year's 6.65 million. Losses were -26.55 million, -18.32% less than in 2024.

Financial Statements

News

There is no news available yet.